Erasca, Inc.

NasdaqGS:ERAS Rapporto sulle azioni

Cap. di mercato: US$768.1m

Erasca Performance dei guadagni passati

Il passato criteri di controllo 0/6

Erasca's earnings have been declining at an average annual rate of -20.8%, while the Biotechs industry saw earnings growing at 19% annually.

Informazioni chiave

-20.8%

Tasso di crescita degli utili

29.2%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavin/a
Rendimento del capitale proprio-35.1%
Margine netton/a
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Oct 15
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16
We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28
Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12
We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Ripartizione dei ricavi e delle spese

Come Erasca guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGS:ERAS Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 240-15839109
31 Mar 240-12739105
31 Dec 230-12538104
30 Sep 230-23137108
30 Jun 230-23637113
31 Mar 230-24036114
31 Dec 220-24334114
30 Sep 220-13831107
30 Jun 220-1492999
31 Mar 220-1412689
31 Dec 210-1232374
30 Sep 210-1541960
30 Jun 210-1191449
31 Mar 210-961037
31 Dec 200-102830

Guadagni di qualità: ERAS is currently unprofitable.

Margine di profitto in crescita: ERAS is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: ERAS is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.

Accelerare la crescita: Unable to compare ERAS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: ERAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: ERAS has a negative Return on Equity (-35.09%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate